Economic evaluation of anti-novel coronavirus infection drugs: a systematic review_Chinese Journal of Evidence-Based Medicine

Authors：

LUO Bingxing ^1,2 , TAO Ying ^1,2 , WENG Junling ^1,2 , LIAN Dai ^1,2 , YAN Juntao ^1,2 , LI Fuming ^1,2 , XIAO Dunming ^1,2 ,  YANG Yi ^1,2 ,  CHEN Yingyao ^1,2

1. School of Public Health, Fudan University, Shanghai 200032, P. R. China;
2. National Health Commission Key Laboratory of Health Technology Assessment, Fudan University, Shanghai 200032, P. R. China;

Corresponding author：

YANG Yi, Email: yangyi18@fudan.edu.cn; CHEN Yingyao, Email: yychen@shmu.edu.cn

Keywords：

COVID-19; Medication; Evaluation of economics

DOI：

10.7507/1672-2531.202302018

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the economic evaluation research of anti-novel coronavirus infection drugs at home and abroad, so as to promote clinical rational drug use. Methods The PubMed, Cochrane Library, EMbase, Web of Science, INAHTA, SinoMed, WanFang Data, and CNKI databases were systematically searched from January 1, 2020 to March 25, 2023, to collect economic evaluation studies related to anti-novel coronavirus infection drugs. Results A total of 22 articles were included, among which 11 studies were conducted from the perspective of health system, and most of the studies performed cost estimation on direct medical costs. The overall compliance rate of the included studies ranged from 42% to 70%, with deficiencies in model setting, incomplete uncertainty analysis, and lack of stakeholder participation. The results showed that immunotherapy drugs (Dexamethasone, Tocilizumab), neutralizing antibody (REGEN-COV antibody), small molecule drugs (Baricitinib, Nirmatrelvir/Ritonavir, Molnupiravir, Favipiravir) and statin were cost-effective. There was some variation in the results of the economic evaluation of Remdesivir. Conclusion At present, there are few studies on the economic evaluation of drug interventions in COVID-19. Existing studies have pointed out that most drug interventions are cost-effective. It is suggested that more standardized pharmacoeconomic evaluation studies based on the actual situation of China epidemic should be carried out in the future.

Citation： LUO Bingxing, TAO Ying, WENG Junling, LIAN Dai, YAN Juntao, LI Fuming, XIAO Dunming, YANG Yi, CHEN Yingyao. Economic evaluation of anti-novel coronavirus infection drugs: a systematic review. Chinese Journal of Evidence-Based Medicine, 2023, 23(5): 549-554. doi: 10.7507/1672-2531.202302018 Copy

1.	WHO. COVID19情况报告. 2022.
2.	国家卫生健康委员会官方网站. 截至12月4日24时新型冠状病毒肺炎疫情最新情况. 2022.
3.	余悦, 邱晓燕, 钟明康. 新型冠状病毒肺炎治疗药物的最新研发进展. 中国医药工业杂志, 2022, 53(6): 775-784.
4.	Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health, 2022, 25(1): 3-9.
5.	Willke RJ, Pizzi LT. CHEERS to updated guidelines for reporting health economic evaluations! Value Health, 2022, 25(1): 1-2.
6.	Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS Ⅱ good practices task force. Value Health, 2022, 25(1): 10-31.
7.	Carta A, Conversano C. Cost utility analysis of remdesivir and dexamethasone treatment for hospitalised COVID-19 patients - a hypothetical study. BMC Health Serv Res, 2021, 21(1): 986.
8.	Oksuz E, Malhan S, Gonen MS, et al. Cost-effectiveness analysis of remdesivir treatment in COVID-19 patients requiring low-flow oxygen therapy: payer perspective in Turkey. Adv Ther, 2021, 38(9): 4935-4948.
9.	Goswami H, Alsumali A, Jiang Y, et al. Cost-effectiveness analysis of molnupiravir versus best supportive care for the treatment of outpatient COVID-19 in adults in the US. Pharmacoeconomics, 2022, 40(7): 699-714.
10.	Kelton K, Klein T, Murphy D, et al. Cost-effectiveness of combination of baricitinib and remdesivir in hospitalized patients with COVID-19 in the United States: a modelling study. Adv Ther, 2022, 39(1): 562-582.
11.	Ruggeri M, Signorini A, Caravaggio S, et al. Estimation model for healthcare costs and intensive care units access for COVID-19 patients and evaluation of the effects of remdesivir in the portuguese context: hypothetical study. Clin Drug Investig, 2022, 42(4): 345-354.
12.	Whittington MD, Pearson SD, Rind DM, et al. The cost-effectiveness of remdesivir for hospitalized patients with COVID-19. Value Health, 2022, 25(5): 744-750.
13.	Jovanoski N, Kuznik A, Becker U, et al. Cost-effectiveness of casirivimab/imdevimab in patients with COVID-19 in the ambulatory setting. J Manag Care Spec Pharm, 2022, 28(5): 555-565.
14.	Sinha P, Linas BP. Combination therapy with tocilizumab and dexamethasone cost-effectively reduces coronavirus disease 2019 mortality. Clin Infect Dis, 2021, 73(11): 2116-2118.
15.	Rafia R, Martyn-St James M, Harnan S, et al. A cost-effectiveness analysis of remdesivir for the treatment of hospitalized patients with COVID-19 in England and Wales. Value Health, 2022, 25(5): 761-769.
16.	Águas R, Mahdi A, Shretta R, et al. Potential health and economic impacts of dexamethasone treatment for patients with COVID-19. Nat Commun, 2021, 12(1): 915.
17.	Ohsfeldt R, Kelton K, Klein T, et al. Cost-effectiveness of baricitinib compared with standard of care: a modeling study in hospitalized patients with COVID-19 in the United States. Clin Ther, 2021, 43(11): 1877-1893.
18.	Chow R, Simone CB, Prsic EH, et al. Cost-effectiveness analysis of statins for the treatment of hospitalized COVID-19 patients. Ann Palliat Med, 2022, 11(7): 2285-2290.
19.	Congly SE, Varughese RA, Brown CE, et al. Treatment of moderate to severe respiratory COVID-19: a cost-utility analysis. Sci Rep, 2021, 11(1): 17787.
20.	Dijk SW, Krijkamp EM, Kunst N, et al. Emerging therapies for COVID-19: the value of information from more clinical trials. Value Health, 2022, 25(8): 1268-1280.
21.	Jiang Y, Cai D, Chen D, et al. Economic evaluation of remdesivir for the treatment of severe COVID-19 patients in China under different scenarios. Br J Clin Pharmacol, 2021, 87(11): 4386-4396.
22.	Jo Y, Jamieson L, Edoka I, et al. Cost-effectiveness of remdesivir and dexamethasone for COVID-19 treatment in South Africa. Open Forum Infect Dis, 2021, 8(3): ofab040.
23.	Jo Y, Kim SB, Radnaabaatar M, et al. Model-based cost-effectiveness analysis of oral antivirals against SARS-CoV-2 in Korea. Epidemiol Health, 2022, 44: e2022034.
24.	Alamer A, Almutairi AR, Halloush S, et al. Cost-effectiveness of Favipiravir in moderately to severely ill COVID-19 patients in the real-world setting of Saudi arabian pandemic referral hospitals. Saudi Pharm J, 2023, 31(4): 510-516.
25.	Lau VI, Fowler R, Pinto R, et al. Cost-effectiveness of remdesivir plus usual care versus usual care alone for hospitalized patients with COVID-19: an economic evaluation as part of the Canadian treatments for COVID-19 (CATCO) randomized clinical trial. CMAJ Open, 2022, 10(3): E807-E817.
26.	Ruggeri M, Signorini A, Caravaggio S. Casirivimab and imdevimab: cost-effectiveness analysis of the treatment based on monoclonal antibodies on outpatients with Covid-19. PLoS One, 2023, 18(2): e0279022.
27.	Savinkina A, Paltiel AD, Ross JS, et al. Population-level strategies for nirmatrelvir/ritonavir prescribing-a cost-effectiveness analysis. Open Forum Infect Dis, 2022, 9(12): ofac637.
28.	Park M, Tan KB, Vasoo S, et al. Estimated health outcomes and costs associated with use of monoclonal antibodies for prevention or mitigation of SARS-CoV-2 infections. JAMA Netw Open, 2022, 5(4): e225750.
29.	Chow R, Im J, Chiu N, et al. The protective association between statins use and adverse outcomes among COVID-19 patients: a systematic review and meta-analysis. PLoS One, 2021, 16(6): e0253576.
30.	Pan H, Peto R, Henao-Restrepo A M, et al. Repurposed antiviral drugs for Covid-19 - interim WHO solidarity trial results. N Engl J Med, 2021, 384(6): 497-511.
31.	Dejmek M, Konkoľová E, Eyer L, et al. Non-nucleotide RNA-dependent RNA polymerase inhibitor that blocks SARS-CoV-2 replication. Viruses, 2021, 13(8): 1585.
32.	WHO. Therapeutics and COVID-19: living guideline. 2022.

1. WHO. COVID19情况报告. 2022.
2. 国家卫生健康委员会官方网站. 截至12月4日24时新型冠状病毒肺炎疫情最新情况. 2022.
3. 余悦, 邱晓燕, 钟明康. 新型冠状病毒肺炎治疗药物的最新研发进展. 中国医药工业杂志, 2022, 53(6): 775-784.
4. Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health, 2022, 25(1): 3-9.
5. Willke RJ, Pizzi LT. CHEERS to updated guidelines for reporting health economic evaluations! Value Health, 2022, 25(1): 1-2.
6. Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS Ⅱ good practices task force. Value Health, 2022, 25(1): 10-31.
7. Carta A, Conversano C. Cost utility analysis of remdesivir and dexamethasone treatment for hospitalised COVID-19 patients - a hypothetical study. BMC Health Serv Res, 2021, 21(1): 986.
8. Oksuz E, Malhan S, Gonen MS, et al. Cost-effectiveness analysis of remdesivir treatment in COVID-19 patients requiring low-flow oxygen therapy: payer perspective in Turkey. Adv Ther, 2021, 38(9): 4935-4948.
9. Goswami H, Alsumali A, Jiang Y, et al. Cost-effectiveness analysis of molnupiravir versus best supportive care for the treatment of outpatient COVID-19 in adults in the US. Pharmacoeconomics, 2022, 40(7): 699-714.
10. Kelton K, Klein T, Murphy D, et al. Cost-effectiveness of combination of baricitinib and remdesivir in hospitalized patients with COVID-19 in the United States: a modelling study. Adv Ther, 2022, 39(1): 562-582.
11. Ruggeri M, Signorini A, Caravaggio S, et al. Estimation model for healthcare costs and intensive care units access for COVID-19 patients and evaluation of the effects of remdesivir in the portuguese context: hypothetical study. Clin Drug Investig, 2022, 42(4): 345-354.
12. Whittington MD, Pearson SD, Rind DM, et al. The cost-effectiveness of remdesivir for hospitalized patients with COVID-19. Value Health, 2022, 25(5): 744-750.
13. Jovanoski N, Kuznik A, Becker U, et al. Cost-effectiveness of casirivimab/imdevimab in patients with COVID-19 in the ambulatory setting. J Manag Care Spec Pharm, 2022, 28(5): 555-565.
14. Sinha P, Linas BP. Combination therapy with tocilizumab and dexamethasone cost-effectively reduces coronavirus disease 2019 mortality. Clin Infect Dis, 2021, 73(11): 2116-2118.
15. Rafia R, Martyn-St James M, Harnan S, et al. A cost-effectiveness analysis of remdesivir for the treatment of hospitalized patients with COVID-19 in England and Wales. Value Health, 2022, 25(5): 761-769.
16. Águas R, Mahdi A, Shretta R, et al. Potential health and economic impacts of dexamethasone treatment for patients with COVID-19. Nat Commun, 2021, 12(1): 915.
17. Ohsfeldt R, Kelton K, Klein T, et al. Cost-effectiveness of baricitinib compared with standard of care: a modeling study in hospitalized patients with COVID-19 in the United States. Clin Ther, 2021, 43(11): 1877-1893.
18. Chow R, Simone CB, Prsic EH, et al. Cost-effectiveness analysis of statins for the treatment of hospitalized COVID-19 patients. Ann Palliat Med, 2022, 11(7): 2285-2290.
19. Congly SE, Varughese RA, Brown CE, et al. Treatment of moderate to severe respiratory COVID-19: a cost-utility analysis. Sci Rep, 2021, 11(1): 17787.
20. Dijk SW, Krijkamp EM, Kunst N, et al. Emerging therapies for COVID-19: the value of information from more clinical trials. Value Health, 2022, 25(8): 1268-1280.
21. Jiang Y, Cai D, Chen D, et al. Economic evaluation of remdesivir for the treatment of severe COVID-19 patients in China under different scenarios. Br J Clin Pharmacol, 2021, 87(11): 4386-4396.
22. Jo Y, Jamieson L, Edoka I, et al. Cost-effectiveness of remdesivir and dexamethasone for COVID-19 treatment in South Africa. Open Forum Infect Dis, 2021, 8(3): ofab040.
23. Jo Y, Kim SB, Radnaabaatar M, et al. Model-based cost-effectiveness analysis of oral antivirals against SARS-CoV-2 in Korea. Epidemiol Health, 2022, 44: e2022034.
24. Alamer A, Almutairi AR, Halloush S, et al. Cost-effectiveness of Favipiravir in moderately to severely ill COVID-19 patients in the real-world setting of Saudi arabian pandemic referral hospitals. Saudi Pharm J, 2023, 31(4): 510-516.
25. Lau VI, Fowler R, Pinto R, et al. Cost-effectiveness of remdesivir plus usual care versus usual care alone for hospitalized patients with COVID-19: an economic evaluation as part of the Canadian treatments for COVID-19 (CATCO) randomized clinical trial. CMAJ Open, 2022, 10(3): E807-E817.
26. Ruggeri M, Signorini A, Caravaggio S. Casirivimab and imdevimab: cost-effectiveness analysis of the treatment based on monoclonal antibodies on outpatients with Covid-19. PLoS One, 2023, 18(2): e0279022.
27. Savinkina A, Paltiel AD, Ross JS, et al. Population-level strategies for nirmatrelvir/ritonavir prescribing-a cost-effectiveness analysis. Open Forum Infect Dis, 2022, 9(12): ofac637.
28. Park M, Tan KB, Vasoo S, et al. Estimated health outcomes and costs associated with use of monoclonal antibodies for prevention or mitigation of SARS-CoV-2 infections. JAMA Netw Open, 2022, 5(4): e225750.
29. Chow R, Im J, Chiu N, et al. The protective association between statins use and adverse outcomes among COVID-19 patients: a systematic review and meta-analysis. PLoS One, 2021, 16(6): e0253576.
30. Pan H, Peto R, Henao-Restrepo A M, et al. Repurposed antiviral drugs for Covid-19 - interim WHO solidarity trial results. N Engl J Med, 2021, 384(6): 497-511.
31. Dejmek M, Konkoľová E, Eyer L, et al. Non-nucleotide RNA-dependent RNA polymerase inhibitor that blocks SARS-CoV-2 replication. Viruses, 2021, 13(8): 1585.
32. WHO. Therapeutics and COVID-19: living guideline. 2022.

Previous Article
Haploidentical hematopoietic stem cell transplantation for beta-thalassemia: a meta-analysis
Next Article
Health economic evaluation in nasopharyngeal carcinoma: a systematic review

Chinese Journal of Evidence-Based Medicine

Economic evaluation of anti-novel coronavirus infection drugs: a systematic review

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content